BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Time to Buy?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $9.66, but opened at $10.05. BioCryst Pharmaceuticals shares last traded at $9.57, with a volume of 1,035,891 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday. Wall Street Zen raised BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd. Finally, Barclays raised their target price on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $16.56.

BioCryst Pharmaceuticals Stock Performance

The firm has a 50-day moving average of $9.92 and a 200-day moving average of $8.54. The firm has a market capitalization of $2.00 billion, a P/E ratio of -36.83, a price-to-earnings-growth ratio of 2.20 and a beta of 1.11.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Headlands Technologies LLC purchased a new stake in BioCryst Pharmaceuticals in the first quarter worth about $32,000. GF Fund Management CO. LTD. bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $33,000. GAMMA Investing LLC raised its stake in shares of BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 5,449 shares during the period. New Age Alpha Advisors LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $62,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at $79,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.